[1]
|
Al-Hamadani, M., Habermann, T.M., Cerhan, J.R., Macon, W.R., Maurer, M.J. and Go, R.S. (2015) Non-Hodgkin Lymphoma Subtype Distribution, Geodemographic Patterns, and Survival in the US: A Longitudinal Analysis of the National Cancer Data Base from 1998 to 2011. American Journal of Hematology, 90, 790-795.
https://doi.org/10.1002/ajh.24086
|
[2]
|
Denizon, N., Baugier de Materre, A., Alani, M., Ghnaya, H., Farhi, J., Besançon, A., et al. (2018) Significant Impact of Immunosuppression on the Incidence of Secondary Malignancies Following Fludarabine, Cyclophosphamide, and Rituximab (FCR) Treatment in Patients with Indolent B-Cell Neoplasms. Leukemia & Lymphoma, 59, 2711-2714.
https://doi.org/10.1080/10428194.2018.1452214
|
[3]
|
Rossi, C., Jégu, J., Mounier, M., Dandoit, M., Colonna, M., Daubisse-Marliac, L., et al. (2015) Risk Assessment of Second Primary Cancer According to Histological Subtype of Non-Hodgkin Lymphoma. Leukemia & Lymphoma, 56, 2876-2882. https://doi.org/10.3109/10428194.2015.1007505
|
[4]
|
Giri, S., Bhatt, V.R., Verma, V., Pathak, R., Gregory Bociek, R., Vose, J.M., et al. (2017) Risk of Second Primary Malignancies in Patients with Follicular Lymphoma: A United States Population-Based Study. Clinical Lymphoma, Myeloma & Leukemia, 17, 569-574. https://doi.org/10.1016/j.clml.2017.06.028
|
[5]
|
Sorigue, M., Prusila, R.E.I., Jauhiainen, J., Mercadal, S., Postila, A., Salmi, P., et al. (2019) Incidence of Solid Cancer in Patients with Follicular Lymphoma. Acta Oncologica, 58, 1564-1569.
https://doi.org/10.1080/0284186X.2019.1643918
|
[6]
|
Herr, M.M., Schonfeld, S.J., Dores, G.M., Engels, E.A., Tucker, M.A., Curtis, R.E., et al. (2019) Risk for Malignancies of Infectious Etiology among Adult Survivors of Specific Non-Hodgkin Lymphoma Subtypes. Blood Advances, 3, 1961-1969. https://doi.org/10.1182/bloodadvances.2019030924
|
[7]
|
Chavez, J.C., Dalia, S., Sandoval-Sus, J., Kharfan-Dabaj, M.A., Al-Ali, N., Komrokji, R., et al. (2015) Second Myeloid Malignancies in a Large Cohort of Patients with Chronic Lymphocytic Leukemia: A Single Institution Experience. Clin Lymphoma Myeloma Leuk, 15, S14-S18. https://doi.org/10.1016/j.clml.2015.03.013
|
[8]
|
Prusila, R.E.I., Sorigue, M., Jauhiainen, J., Mercadal, S., Postila, A., Salmi, P., et al. (2019) Risk of Secondary Haematological Malignancies in Patients with Follicular Lymphoma: An Analysis of 1028 Patients Treated in the Rituximab Era. British Journal of Haematology, 187, 364-371. https://doi.org/10.1111/bjh.16090
|
[9]
|
Shadman, M., Li, H., Rimsza, L., Leonard, J.P., Kaminski, M.S., Braziel, R.M., et al. (2018) Continued Excellent Outcomes in Previously Untreated Patients with Follicular Lymphoma after Treatment with CHOP Plus Rituximab or CHOP Plus 131I-Tositumomab: Long-Term Follow-Up of Phase III Randomized Study SWOG-S0016. Journal of Clinical Oncology, 36, 697-703. https://doi.org/10.1200/JCO.2017.74.5083
|
[10]
|
Maurer, C., Langerbeins, P., Bahlo, J., Cramer, P., Fink, A.M., Pflug, N., et al. (2016) Effect of First-Line Treatment on Second Primary Malignancies and Richter’s Transformation in Patients with CLL. Leukemia, 30, 2019-2025.
https://doi.org/10.1038/leu.2016.113
|
[11]
|
Falchi, L, Vitale, C., Keating, M.J., Lerner, S., Wang, X., Elhor Gbito, K.Y., et al. (2016) Incidence and Prognostic Impact of Other Cancers in a Population of Long-Term Survivors of Chronic Lymphocytic Leukemia. Annals of Oncology, 27, 1100-1106. https://doi.org/10.1093/annonc/mdw072
|
[12]
|
Bond, D.A., Huang, Y., Fisher, J.L., Ruppert, A.S., Owen, D.H., Bertino, E.M., et al. (2020) Second Cancer Incidence in CLL Patients Receiving BTK Inhibitors. Leukemia, 34, 3197-3205. https://doi.org/10.1038/s41375-020-0987-6
|
[13]
|
Lenartova, A., Johannesen, T.B. and Tjønnfjord, G.E. (2020) Chronic Lymphocytic Leukemia and Secondary Hematological Malignancies: A Nation-Wide Cancer Registry Study. European Journal of Haematology, 104, 546-553.
https://doi.org/10.1111/ejh.13396
|
[14]
|
Ishdorj, G., Beiggi, S., Nugent, Z., Streu, E., Banerji, V., Dhaliwal, D., et al. (2019) Risk Factors for Skin Cancer and Solid Tumors in Newly Diagnosed Patients with Chronic Lymphocytic Leukemia and the Impact of Skin Surveillance on Survival. Leukemia & Lymphoma, 60, 3204-3213. https://doi.org/10.1080/10428194.2019.1620941
|
[15]
|
Mulligan, S.P., Shumack, S. and Guminski, A. (2019) Chronic Lymphocytic Leukemia, Skin and Other Second Cancers. Leukemia & Lymphoma, 60, 3104-3106. https://doi.org/10.1080/10428194.2019.1665669
|
[16]
|
Yang, Y., Yang, Y. and Yan, S. (2021) Risk and Survival of Second Primary Malignancies Following Diagnosis of Gastric Mucosa-Associated Lymphoid Tissue Lymphomas: A Population-Based Study. Current Problems in Cancer, Article ID: 100735. (In Press) https://doi.org/10.1016/j.currproblcancer.2021.100735
|
[17]
|
Amiot, A., Jooste,V., Gagniere, C., Lévy, M., Copie-Bergman, C., Dupuis, J. et al. (2017) Second Primary Malignancies in Patients Treated for Gastric Mucosa-Associated Lymphoid Tissue Lymphoma. Leukemia & Lymphoma, 58, 2057-2064. https://doi.org/10.1080/10428194.2017.1283033
|
[18]
|
Tajika, M., Matsuo, K., Ito, H., Chihara, D., Bhatia, V., Kondo, S., et al. (2014) Risk of Second Malignancies in Patients with Gastric Marginal Zone Lymphomas of Mucosa Associate Lymphoid Tissue (MALT). Journal of Gastroenterology, 49, 843-852. https://doi.org/10.1007/s00535-013-0844-8
|
[19]
|
Castillo, J.J., Olszewski, A.J., Hunter, Z.R., Kanan, S., Meid, K. and Treon, S.P. (2015) Incidence of Secondary Malignancies among Patients with Waldenström Macroglobulinemia: An Analysis of the SEER Database. Cancer, 121, 2230-2236. https://doi.org/10.1002/cncr.29334
|
[20]
|
Wiber, M., Maitre, E., Poncet, J.M., Duchenet, V., Damaj, G., Cornet, E., et al. (2020) A Population-Based Study of Hairy Cell Leukemia over a Period of 20 Years. Cancer Treatment and Research Communications, 25, Article ID: 100236. https://doi.org/10.1016/j.ctarc.2020.100236
|
[21]
|
Paillassa, J., Cornet, E., Noel, S., Tomowiak, C., Lepretre, S., Vaudaux, S., et al. (2020) Analysis of a Cohort of 279 Patients with Hairy-Cell Leukemia (HCL): 10 Years of Follow-Up. Blood Cancer Journal, 10, Article No. 62.
https://doi.org/10.1038/s41408-020-0328-z
|
[22]
|
Pirani, M., Marcheselli, R., Marcheselli, L., Bari, A., Federico, M. and Sacchi, S. (2011) Risk for Second Malignancies in Non-Hodgkin’s Lymphoma Survivors: A Meta-Analysis. Annals of Oncology, 22, 1845-1858.
https://doi.org/10.1093/annonc/mdq697
|
[23]
|
Luminari, S., Ferrari, A., Manni, M., Dondi, A., Chiarenza, A., Merli, F., et al. (2018) Long-Term Results of the FOLL05 Trial Comparing R-CVP versus R-CHOP versus R-FM for the Initial Treatment of Patients with Advanced-Stage Symptomatic Follicular Lymphoma. Journal of Clinical Oncology, 36, 689-696.
https://doi.org/10.1200/JCO.2017.74.1652
|
[24]
|
Flinn, I.W., van der Jagt, R., Kahl, B., Wood, P., Hawkins, T., MacDonald, D., et al. (2019) First-Line Treatment of Patients with Indolent Non-Hodgkin Lymphoma or Mantle-Cell Lymphoma with Bendamustine Plus Rituximab Versus R-CHOP or R-CVP: Results of the BRIGHT 5-Year Follow-Up Study. Journal of Clinical Oncology, 37, 984-991.
https://doi.org/10.1200/JCO.18.00605
|
[25]
|
Hiddemann, W., Barbui, A.M., Canales, M.A., Cannell, P.K., Collins, G.P., Dürig, J., et al. (2018) Immunochemotherapy with Obinutuzumab or Rituximab for Previously Untreated Follicular Lymphoma in the GALLIUM Study: Influence of Chemotherapy on Efficacy and Safety. Journal of Clinical Oncology, 36, 2395-2404.
https://doi.org/10.1200/JCO.2017.76.8960
|
[26]
|
Olszewski, A.J., Butera, J.N., Reagan, J.L. and Castillo, J.J. (2020) Outcomes of Bendamustine- or Cyclophosphamide-Based First-Line Chemotherapy in Older Patients with Indolent B-Cell Lymphoma. American Journal of Hematology, 95, 354-361. https://doi.org/10.1002/ajh.25707
|
[27]
|
Federico, M., Luminari, S., Dondi, A., Tucci, A., Vitolo, U., Rigacci, L., et al. (2013) R-CVP versus R-CHOP versus R-FM for the Initial Treatment of Patients with Advanced-Stage Follicular Lymphoma: Results of the FOLL05 Trial Conducted by the Fondazione Italiana Linfomi. Journal of Clinical Oncology, 31, 1506-1513.
https://doi.org/10.1200/JCO.2012.45.0866
|
[28]
|
Colovic, M., Suvajdzic, N., Jankovic, G., Tomin, D., Čolović, N., Denčić Fekete, M., et al. (2011) Therapy-Related Myelodysplastic Syndrome and Acute Myeloid Leukemia in Patients with Chronic Lymphocytic Leukemia Treated with Fludarabine and Cyclophosphamide. Biomedicine & Pharmacotherapy, 65, 319-321.
https://doi.org/10.1016/j.biopha.2011.04.006
|
[29]
|
Carney, D.A., Westerman, D.A., Tam, C.S., Milner, A., Prince, H.M., Kenealy, M, et al. (2010) Therapy-Related Myelodysplastic Syndrome and Acute Myeloid Leukemia Following Fludarabine Combination Chemotherapy. Leukemia, 24, 2056-2062. https://doi.org/10.1038/leu.2010.218
|
[30]
|
Epperla, N., Pham, A.Q., Burnette, B.L., Wiseman, G.A., Habermann, T.M., Macon, W.R., et al. (2017) Risk of Histological Transformation and Therapy-Related Myelodysplasia/Acute Myeloid Leukaemia in Patients Receiving Radioimmunotherapy for Follicular Lymphoma. British Journal of Haematology, 178, 427-433.
https://doi.org/10.1111/bjh.14688
|
[31]
|
Byrd, J.C., Hillmen, P.O., O’Brien, S., Barrientos, J.C., Reddy, N.M., Coutre, S., et al. (2019) Long-Term Follow-Up of the RESONATE Phase 3 Trial of Ibrutinib vs Ofatumumab. Blood, 133, 2031-2042.
https://doi.org/10.1182/blood-2018-08-870238
|
[32]
|
Coutre, S.E., Byrd, J.C., Hillmen, P., Barrientos, J.C., Barr, P.M., Devereux, S., et al. (2019) Long-Term Safety of Single-Agent Ibrutinib in Patients with Chronic Lymphocytic Leukemia in 3 Pivotal Studies. Blood Advanves, 3, 1799-1807. https://doi.org/10.1182/bloodadvances.2018028761
|
[33]
|
Treon, S.P., Tripsas, C.K., Meid, K., Warren, D., Varma, G., Green, R., et al. (2015) Ibrutinib in Previously Treated Waldenström’s Macroglobulinemia. New England Journal of Medicine, 372, 1430-1440.
https://doi.org/10.1056/NEJMoa1501548
|
[34]
|
Tiacci, E., DeCarolis, L., Simonetti, E., Capponi, M., Ambrosetti, A., Lucia, E., et al. (2021) Vemurafenib plus Rituximab in Refractory or Relapsed Hairy-Cell Leukemia. New England Journal of Medicine, 384, 1810-1823.
https://doi.org/10.1056/NEJMoa2031298
|
[35]
|
Tiacci, E., Park, J.H., DeCarolis, L., Chung, S.S., Broccoli, A., Scott, S., et al. (2015) Targeting Mutant BRAF in Relapsed or Refractory Hairy-Cell Leukemia. New England Journal of Medicine, 373, 1733-1747.
https://doi.org/10.1056/NEJMoa1506583
|